Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 19/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | BRD2 | P25440 | 1/20 | 0.43 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16145427 | 0.88 | BRD4 (0.82) | BRD4LMNATSHRBRD2BRD3 | |
| SCHEMBL16145238 | 0.86 | BRD4 (1.00) | BRD4LMNATSHRBRD2BRD3 | |
| SCHEMBL16145273 | 0.84 | BRD4 (0.64) | BRD4 | |
| SCHEMBL16145544 | 0.82 | BRD4 (0.71) | BRD4LMNA | |
| SCHEMBL16145187 | 0.82 | BRD4 (0.62) | BRD4 | |
| SCHEMBL16059486 | 0.81 | BRD4 (1.00) | BRD4 | |
| SCHEMBL19565468 | 0.81 | BRD4 (0.61) | BRD4 | |
| SCHEMBL16060672 | 0.80 | BRD4 (0.68) | BRD4LMNABRD2BRD3 | |
| SCHEMBL19968960 | 0.79 | BRD4 (0.67) | BRD4LMNA | |
| SCHEMBL16145282 | 0.79 | BRD4 (0.57) | BRD4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970265-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20180072722-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2018-03-15 | — | — | US | disclosed |
| US-20180072722-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2018-03-15 | — | — | US | disclosed |
| US-20180072722-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2018-03-15 | — | — | US | disclosed |
| US-9822109-B2 | Heterocyclic compounds and uses thereof | PLEXXIKON INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822109-B2 | Heterocyclic compounds and uses thereof | PLEXXIKON INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822109-B2 | Heterocyclic compounds and uses thereof | PLEXXIKON INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170320899-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320899-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320899-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-9718847-B2 | Heterocyclic compounds and uses thereof | PLEXXIKON INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718847-B2 | Heterocyclic compounds and uses thereof | PLEXXIKON INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718847-B2 | Heterocyclic compounds and uses thereof | PLEXXIKON INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160068528-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2016-03-10 | — | — | US | disclosed |
| US-20160068528-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2016-03-10 | — | — | US | disclosed |
| US-20160068528-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2016-03-10 | — | — | US | disclosed |
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2015-05-14 | — | — | US | disclosed |
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2015-05-14 | — | — | US | disclosed |
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2015-05-14 | — | — | US | disclosed |
| US-20140303121-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303121-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, CYP2C19 | BRD4 1365/4885LMNA 1294/4885TSHR 3486/4885 |
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, CYP2C19 | BRD4 1365/4885LMNA 1294/4885TSHR 3486/4885 |
| US-20170320899-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, CYP2C19 | BRD4 1365/4885LMNA 1294/4885TSHR 3486/4885 |
| US-20160068528-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, CYP2C19 | BRD4 1365/4885LMNA 1294/4885TSHR 3486/4885 |
| US-20180072722-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, CYP2C19 | BRD4 1365/4885LMNA 1294/4885TSHR 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.